Corcept Therapeutics Management
Management criteria checks 4/4
Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 25.17 years. total yearly compensation is $7.35M, comprised of 12.2% salary and 87.8% bonuses, including company stock and options. directly owns 2.74% of the company’s shares, worth $71.70M. The average tenure of the management team and the board of directors is 3.3 years and 22.4 years respectively.
Key information
Joseph Belanoff
Chief executive officer
US$7.4m
Total compensation
CEO salary percentage | 12.2% |
CEO tenure | 25.2yrs |
CEO ownership | 2.7% |
Management average tenure | 3.3yrs |
Board average tenure | 22.4yrs |
Recent management updates
Recent updates
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Corcept extends distribution agreement for Cushing’s syndrome drug
Sep 23Corcept Therapeutics: A Status Check
Sep 06Corcept cut to Hold at Truist on balanced risk-reward setup
Aug 01Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer
Jun 29I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease
Jun 09Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?
Feb 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | n/a | n/a | US$105m |
Sep 30 2023 | n/a | n/a | US$91m |
Jun 30 2023 | n/a | n/a | US$94m |
Mar 31 2023 | n/a | n/a | US$94m |
Dec 31 2022 | US$7m | US$896k | US$101m |
Sep 30 2022 | n/a | n/a | US$117m |
Jun 30 2022 | n/a | n/a | US$113m |
Mar 31 2022 | n/a | n/a | US$112m |
Dec 31 2021 | US$11m | US$844k | US$113m |
Sep 30 2021 | n/a | n/a | US$106m |
Jun 30 2021 | n/a | n/a | US$98m |
Mar 31 2021 | n/a | n/a | US$99m |
Dec 31 2020 | US$6m | US$770k | US$106m |
Sep 30 2020 | n/a | n/a | US$109m |
Jun 30 2020 | n/a | n/a | US$114m |
Mar 31 2020 | n/a | n/a | US$106m |
Dec 31 2019 | US$5m | US$708k | US$94m |
Sep 30 2019 | n/a | n/a | US$87m |
Jun 30 2019 | n/a | n/a | US$78m |
Mar 31 2019 | n/a | n/a | US$76m |
Dec 31 2018 | US$6m | US$680k | US$75m |
Sep 30 2018 | n/a | n/a | US$152m |
Jun 30 2018 | n/a | n/a | US$148m |
Mar 31 2018 | n/a | n/a | US$142m |
Dec 31 2017 | US$4m | US$647k | US$129m |
Compensation vs Market: Joseph's total compensation ($USD7.35M) is about average for companies of similar size in the US market ($USD6.32M).
Compensation vs Earnings: Joseph's compensation has been consistent with company performance over the past year.
CEO
Joseph Belanoff (66 yo)
25.2yrs
Tenure
US$7,352,757
Compensation
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 25.2yrs | US$7.35m | 2.74% $ 71.7m | |
CFO & Treasurer | 3yrs | US$1.89m | 0.0092% $ 241.4k | |
Chief Scientific Officer | 3.7yrs | US$3.11m | 0.090% $ 2.4m | |
President of Endocrinology | 7.9yrs | US$3.71m | 0.10% $ 2.7m | |
Chief Business Officer & Secretary | 10.2yrs | US$3.20m | 0.044% $ 1.1m | |
Chief Accounting Officer | 3.7yrs | no data | 0.0071% $ 185.3k | |
Chief Human Resources & Communications Officer | 2.7yrs | no data | no data | |
Chief Development Officer | 2.6yrs | no data | 0.0058% $ 152.8k | |
President of Emerging Markets | less than a year | no data | no data | |
President of Oncology | less than a year | no data | no data |
3.3yrs
Average Tenure
52.5yo
Average Age
Experienced Management: CORT's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 25.2yrs | US$7.35m | 2.74% $ 71.7m | |
Independent Director | 25.2yrs | US$311.77k | 5.13% $ 134.5m | |
Independent Director | 19.7yrs | US$328.27k | 1.17% $ 30.8m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Chairman | 25.2yrs | US$678.99k | 2.14% $ 56.1m | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 4yrs | US$330.77k | 0% $ 0 | |
Member of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 4.5yrs | US$307.77k | 0% $ 0 |
22.4yrs
Average Tenure
67.5yo
Average Age
Experienced Board: CORT's board of directors are seasoned and experienced ( 22.4 years average tenure).